Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the...
April 08, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™ JOTROL™ development programs remain tariff-exempt; consumer...
January 13, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...